$LFST

LifeStance Health Group reported Q2 2026 revenue growth of 26%, driven by higher visit volumes and a 6% rise in revenue per visit, and said visits per clinician rose 7% YoY. The company raised full-year 2026 guidance to $1.685B-$1.725B revenue and 13.2% adjusted EBITDA margins, approved a new $100M buyback, and reported Q2 free cash flow of $88M.

LifeStance (LFST) reported Q2 2026 results on an earnings call. Revenue rose to $435 million (+26%) on 2.6 million visits (+19%) and total revenue per visit of $167 (+6%). Adjusted EBITDA was $66 million (+94%) with a 15.2% margin. Full-year 2026 revenue guidance was raised to $1.685-$1.725 billion and adjusted EBITDA to $215-$235 million.

LifeStance Health Group Inc. (LFST) reported Q2 net income of $23.6 million, or 6 cents per share, topping Wall Street expectations. Revenue was $435.4 million versus an expected $414.3 million, according to Zacks Investment Research. For the quarter ending September, the company forecast revenue of $420 million to $440 million, and full-year revenue of $1.69 billion to $1.73 billion.

LifeStance Health Group, Inc. (LFST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lfst-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Investor Relations Contact Monica Prokocki VP of Finance & Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook Announc

LifeStance Health (NASDAQ: LFST) is set to report Q2 earnings Thursday. The company previously beat revenue expectations with $403.5 million revenue, up 21.2% year over year. For Q2, analysts expect revenue growth of 20.1% YoY. The article cites an average analyst price target of $12 versus a $10.25 share price.

LifeStance Health Group, Inc. (LFST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001845257 0001845257 2026-07-02 2026-07-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2

Bessler Robert sold 894,337 indirectly-held shares of LifeStance Health Group, Inc. (LFST) at $10.13 ($9.06M total) across 2 trades on 2026-06-26 under a Rule 10b5-1 trading plan.

LifeStance Health, ARC Health, and Beacon Behavioral Partners have refined their acquisition strategies, shifting from pure growth to focusing on integration, fit, and sustainability. LifeStance is returning to M&A with a focus on tuck-in deals that expand outpatient footprints and service lines, while ARC Health and Beacon Behavioral are prioritizing strong partner alignment and clinical quality. All three companies emphasize culture and compliance fit, and avoid targets with weak compliance, low scalability, or those outside their specialized outpatient mental health focus.

LifeStance Health Group, Inc. (NASDAQ: LFST) filed an 8-K report detailing an underwritten offering of 35,000,000 shares of common stock by existing selling stockholders. The company itself did not receive any proceeds from this sale but separately agreed to repurchase 6,000,000 of these shares from the underwriter. The offering closed on May 12, 2026, and was managed by J.P. Morgan Securities LLC.

LifeStance Health Group Inc. (NASDAQ:LFST) reached a two-year high after reporting a 1,900% increase in Q1 net income to $14.2 million, with revenues rising 21% to $403.5 million. CEO Dave Bourdon attributed the strong performance to growing demand for mental healthcare. The company subsequently raised its full-year revenue growth forecast to $1.64 billion-$1.68 billion.